BIOMOTION PHARMA ApS: Financial statements 2020
CVR: 12928203
Source: annual report 2020, Danish Business Authority
01/10/2019 – 30/09/2020
BIOMOTION PHARMA ApS (CVR 12928203) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,250 and a net result of DKK -1,250 compared with DKK -1,501 the year before. Equity in the 2020 report amounted to DKK 1,250. The solvency ratio was 50%.
- Gross Profit
- DKK -1,250
- Profit/Loss
- DKK -1,250
- Equity
- DKK 1,250
- Total Assets
- DKK 2,500
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -1 t. | -1 t. | 1 t. | - |
| 2019 | - | -2 t. | -2 t. | 3 t. | - |
| 2018 | - | 5 t. | 5 t. | 4 t. | - |
| 2017 | - | - | 0 | -999 | - |
| 2016 | - | 0 | 0 | -999 | - |
Official annual report
How creditworthy is BIOMOTION PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of September 25, 2020, EY Godkendt Revisionspartnerselskab has been appointed auditor of BIOMOTION PHARMA ApS.
As of September 25, 2020, JUT NR. 2180 A/S has stepped down as auditor of BIOMOTION PHARMA ApS.
About BIOMOTION PHARMA ApS
BIOMOTION PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 1989. The company is in liquidation. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named HANDEL OG INVESTERING AF 1989 ApS and DANSK FARMASAN A/S. The management consists of Michael Rasmussen. The company is owned by Michael Rasmussen. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -4,000 and a net result of DKK -4,202 compared with DKK -6,460 the year before. Equity in the 2025 report amounted to DKK -892.